Adjuvant Therapy Benefits Pancreatic Cancer Patients with Short Neoadjuvant Duration or Microscopic Margins

A retrospective study on 529 pancreatic cancer patients after neoadjuvant therapy reveals adjuvant therapy’s survival benefit. For the entire cohort, no significant overall survival difference was observed. However, subgroup analysis shows a survival advantage with adjuvant therapy for those with less than 4 months of neoadjuvant treatment or microscopic margin positive surgical resections. This insight underscores the nuanced impact of adjuvant therapy in specific pancreatic cancer patient subsets.